Upholding of WARF stem cell patent reversed
By The Business Journal of Milwaukee,
The Business Journal of Milwaukee
| 05. 03. 2010
The U.S. Patent and Trademark Office's Board of Appeals and Interference has reversed an earlier decision from the Patent Office's re-examination division that upheld the claims of one of the stem cell lines held by the Wisconsin Alumni Research Foundation.
The patent covers one of the three key stem cell lines that were challenged through re-examination proceedings initiated in October 2006 at the request of consumer watchdog groups New York City-based Public Patent Foundation and the Santa Monica, Calif.-based Foundation for Taxpayer and Consumer Rights, now called Consumer Watchdog.
The re-examination division upheld the validity of the patents in mid-2008, and the groups were allowed to challenge one of the patents in an appeal to the Board of Appeals and Interference.
The groups argue that the work done by University of Wisconsin researcher James Thomson to isolate stem cell lines was obvious in the light of previous scientific research, making his work unpatentable. The groups claimed the three WARF patents were "impeding scientific progress and driving vital stem cell research overseas."
The patent office rejected the arguments by the groups...
Related Articles
By Carl Zimmer, The New York Times | 06.04.2026
Scientists at Columbia University have edited the DNA of early human embryos with unprecedented accuracy, an achievement that could open the way to babies engineered with particular characteristics.
The prospect has fueled controversy for years. On the one hand, the...
By Calder McHugh, Politico | 05.15.2026
There will come a time, in the not-so-distant future, when you decide to stick a computer chip in your brain.
At least, that’s what D. Scott Phoenix told the audience at TED 2026 in Vancouver last month.
“Someone you work...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...